The IP War Goes Global: Why Intellectual Property Has Become the Central Front in Technology Competition
Intellectual property litigation was, for most of the twentieth century, a specialist legal discipline operating at the margins of corporate strategy. Patent disputes between competitors were bilateral affairs resolved in national courts, with outcomes that mattered for product markets but rarely for geopolitical positioning. That characterisation has become obsolete. The first quarter of the twenty-first century has turned intellectual property — in patents, trade secrets, software copyrights, and semiconductor design rights — into the primary terrain on which the technology competition between the United States, China, and Europe is being fought. The stakes are no longer market share in individual product categories. They are industrial leadership in the sectors that will define economic and military capability through the middle of the century: semiconductors, artificial intelligence, biotechnology, quantum computing, and the software infrastructure that connects them.
The shift has been driven by three overlapping forces. The first is the recognition by all major powers that technology leadership cannot be purchased — it must be developed domestically, protected legally, and denied to adversaries through export controls, investment screening, and IP enforcement. The second is the extraordinary concentration of commercially valuable IP in a small number of US and European firms whose patent portfolios, trade secrets, and software capabilities represent strategic assets of national importance rather than purely private property. The third is the sustained and well-documented campaign by Chinese state-backed actors to acquire, replicate, or circumvent Western IP through a combination of legal licensing, forced technology transfer in market access negotiations, and intelligence-directed economic espionage — a campaign that has accelerated as legitimate technology acquisition has been restricted by export controls.
Trade Secret Theft: The Invisible IP War That Courts Are Now Making Visible
Patent litigation is the visible face of IP conflict — public filings, published decisions, measurable damage awards. Trade secret theft is the invisible face, and by most estimates the more economically significant one. The US Office of the Director of National Intelligence has published annual threat assessments consistently identifying China as the most significant state sponsor of economic espionage targeting US trade secrets, with losses estimated in the hundreds of billions of dollars annually across sectors including semiconductors, aerospace, biotechnology, and advanced manufacturing processes.
What has changed in the past five years is the legal and institutional framework for addressing trade secret theft at scale. The Defend Trade Secrets Act, passed in 2016, created a federal civil cause of action for trade secret misappropriation that has been used in a growing number of cases involving alleged state-sponsored actors. The Department of Justice's China Initiative — discontinued in its original form in 2022 but substantially continued under different organisational labels — produced a significant number of criminal prosecutions of individuals accused of stealing trade secrets for the benefit of Chinese state-linked entities. European equivalents, including the EU Trade Secrets Directive transposed by member states from 2018 onward, have strengthened civil remedies across jurisdictions. The legal infrastructure for trade secret protection has strengthened considerably; enforcement in cases involving sophisticated state actors remains genuinely difficult.
The Semiconductor IP Chokepoint: TSMC, ARM, and the Architecture of Dependence
No single IP concentration in the global technology economy is more strategically significant than the intersection of ARM's instruction set architecture licenses and TSMC's advanced node manufacturing capability. ARM's architecture underpins essentially every mobile processor in the world and a growing share of data centre, automotive, and edge computing chips. TSMC manufactures the overwhelming majority of the world's most advanced semiconductor chips, including those designed by Apple, NVIDIA, AMD, and the leading fabless companies whose products define the performance frontier of AI computing. The geographic concentration of TSMC's leading-edge capacity in Taiwan, combined with ARM's UK headquarters and its acquisition by SoftBank from its earlier attempted acquisition by NVIDIA, creates a IP-and-manufacturing chokepoint of extraordinary strategic sensitivity.
China's response to its exclusion from advanced semiconductor manufacturing through US export controls has been a massive state-directed investment in domestic IP development and manufacturing capability. SMIC, Yangtze Memory Technologies, and a network of state-backed fabless design companies are racing to develop capabilities that reduce dependence on foreign IP and equipment. The pace of progress has surprised some Western analysts, though the consensus assessment remains that China is 3–5 years behind the leading edge in advanced logic manufacturing and further behind in the EUV lithography equipment that enables it. The strategic calculation driving Chinese investment is not near-term parity but long-term autonomy — the ability to produce militarily relevant semiconductor capability domestically regardless of what export controls or IP licensing restrictions a future geopolitical confrontation might trigger.
AI and the New IP Frontier: Training Data, Model Weights, and the Copyright Reckoning
Artificial intelligence has created a new and legally unsettled IP frontier that is generating litigation at a pace that will reshape the framework for intellectual property in the digital economy over the next decade. The core legal questions — whether large language models trained on copyrighted text infringe on the works they were trained on, whether model weights constitute protectable IP, and who owns the outputs of generative AI systems — are being litigated simultaneously in multiple US federal courts with outcomes that will have global implications given the dominance of US-headquartered AI developers.
The cases brought by the New York Times against OpenAI and Microsoft, by music publishers against AI music generation platforms, and by visual artists against image generation companies represent the leading edge of a much larger wave of AI copyright litigation. The legal theory in each case differs in detail, but the central question is consistent: does training an AI system on copyrighted works without licensing constitute infringement? The AI developers argue that training is transformative use; the rights holders argue that systematic ingestion of protected works for commercial benefit without compensation is straightforward copying at unprecedented scale. The resolution of this question will determine whether AI training data must be licensed — and if so, who captures the enormous economic value of the data that has made current AI systems possible. For IP consulting services, IP litigation practices, and IP rights protection businesses, the AI copyright wave represents the largest market development opportunity in the sector's history.
The Pharma Patent Cliff and the Biologic IP Battle
The pharmaceutical industry faces a patent cliff of extraordinary scale through 2030, with branded drugs generating over $300 billion in annual global revenues losing patent protection over the next six years. The response from originator companies — extending protection through secondary patents on formulations, delivery devices, dosing regimens, and manufacturing processes — has intensified the litigation between branded pharma and biosimilar developers to levels that make the pharma IP litigation market among the most active and economically significant in the world. The patent thicket strategy employed by AbbVie on Humira — the world's highest-revenue drug — is the paradigm case: over 130 patents covering different aspects of the drug, dosing device, and manufacturing process created a protection structure that delayed biosimilar competition in the US for years beyond the core compound patent expiry.
The biologic and biosimilar IP battlefield is structurally different from small-molecule pharma patent disputes, and more difficult to navigate for both challengers and originators. Biosimilars are not chemically identical to reference biologics — they are highly similar but not identical large-molecule drugs whose manufacturing processes are themselves complex and proprietary. Patent disputes in this space involve not just the compound patent and formulation patents but manufacturing process patents that are among the most technically complex and commercially sensitive IP assets that pharmaceutical companies hold. The interplay between US Biologics Price Competition and Innovation Act provisions, European biosimilar regulatory pathways, and the patent litigation strategies of both originator and biosimilar companies creates a legal and commercial complexity that specialist IP litigation practices and consulting firms are well-positioned to navigate — and that will generate sustained litigation spend across the sector for the remainder of the decade.
The IP Services Market Response: Scale, Specialisation, and Technology Transformation
The confluence of geopolitical IP competition, AI copyright litigation, pharmaceutical patent complexity, and the globalisation of innovation is creating exceptional demand for IP services across the spectrum from prosecution and portfolio management to litigation support and enforcement. The IP services market is responding with both consolidation and specialisation. At the consolidation end, Clarivate's acquisition of CPA Global, Questel's growth through acquisition of patent analytics and prosecution services firms, and the expansion of the large-scale IP management platforms signal a market moving toward integrated service providers capable of managing global portfolios across multiple jurisdictions and IP categories.
At the specialisation end, boutique IP litigation practices, AI-specific IP advisory firms, and forensic IP valuation specialists are capturing premium mandates that require deep domain expertise that integrated platforms cannot easily commoditise. The technology transformation of IP services — AI-assisted patent searching, automated prior art analysis, machine learning for portfolio risk assessment — is changing the economics of the work without eliminating the need for human judgment at the most complex and highest-value junctures. The IP services firms that are investing in proprietary technology platforms while maintaining the specialist expertise that clients require for high-stakes disputes are well-positioned for a decade in which IP has moved from legal overhead to strategic asset — and in which the management and protection of that asset has become a board-level priority across industries that previously treated it as a back-office function.